EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Post-LOEefavirenz; emtricitabine; tenofovir disoproxil fumarate
ANDAORALTABLET
Approved
Oct 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (efavirenz; emtricitabine; tenofovir disoproxil fumarate) by Molecular Devices is efavirenz, emtricitabine and tenofovir disoproxil fumarate is a fixed-dose combination of antiviral drugs efv, ftc, and tdf [see ]. First approved in 2023.
Drug data last refreshed 18h ago
Mechanism of Action
Efavirenz, emtricitabine and tenofovir disoproxil fumarate is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.